gemfibrozil has been researched along with Diabetes Mellitus in 18 studies
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months." | 9.08 | A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995) |
| "Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis." | 7.70 | A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. ( Boran, M; Gökçe, V; Koçak, B; Korkmaz, S; Ozdemir, O; Uzun, Y, 2000) |
| "In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months." | 5.08 | A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995) |
| "Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis." | 3.70 | A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. ( Boran, M; Gökçe, V; Koçak, B; Korkmaz, S; Ozdemir, O; Uzun, Y, 2000) |
| "Since dyslipidemia is common in diabetes and is associated with increased cardiovascular risk, we tested the hypothesis that Thr-54 is associated with increased cardiovascular risk in patients with diabetes." | 2.73 | Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). ( Bloomfield, H; Brousseau, ME; Collins, D; Georgopoulos, A; O'Connor, JJ; Ordovas, JM; Robins, SJ; Schaefer, EJ, 2007) |
| "The gemfibrozil was well tolerated." | 2.65 | The effect of gemfibrozil on serum lipids in diabetic patients. ( Konttinen, A; Kuisma, I; Ojala, K; Pohjola, S; Ralli, R, 1979) |
| "Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension." | 2.41 | A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Song, H | 1 |
| Bai, J | 1 |
| Xiu, J | 1 |
| Wu, G | 1 |
| Zhang, L | 1 |
| Wu, Y | 1 |
| Qu, Y | 1 |
| Kayıkçıoğlu, M | 1 |
| Shahbazova, S | 1 |
| İbrahimov, F | 1 |
| Can, LH | 1 |
| King, D | 1 |
| Armstrong, MJ | 1 |
| Khoshakhlagh, AH | 1 |
| Yazdanirad, S | 1 |
| Laal, F | 1 |
| Sarsangi, V | 1 |
| Bloomgarden, ZT | 1 |
| Drexler, A | 1 |
| Lee, CY | 1 |
| Huang, KH | 1 |
| Lin, CC | 1 |
| Tsai, TH | 1 |
| Shih, HC | 1 |
| Angulo, P | 1 |
| Davidson, MH | 1 |
| Ganda, OP | 1 |
| Kon, YC | 1 |
| Tai, ES | 1 |
| Collins, D | 2 |
| Robins, SJ | 2 |
| O'Connor, JJ | 2 |
| Bloomfield, HE | 1 |
| Ordovas, JM | 2 |
| Schaefer, EJ | 2 |
| Brousseau, ME | 2 |
| Trivedi, NR | 1 |
| Cong, Z | 1 |
| Nelson, AM | 1 |
| Albert, AJ | 1 |
| Rosamilia, LL | 1 |
| Sivarajah, S | 1 |
| Gilliland, KL | 1 |
| Liu, W | 1 |
| Mauger, DT | 1 |
| Gabbay, RA | 1 |
| Thiboutot, DM | 1 |
| Georgopoulos, A | 1 |
| Bloomfield, H | 1 |
| Ohrvall, M | 1 |
| Lithell, H | 1 |
| Johansson, J | 1 |
| Vessby, B | 1 |
| Bell, DS | 1 |
| Ovalle, F | 1 |
| Ozdemir, O | 1 |
| Boran, M | 1 |
| Gökçe, V | 1 |
| Uzun, Y | 1 |
| Koçak, B | 1 |
| Korkmaz, S | 1 |
| Malloy, MJ | 1 |
| Kane, JP | 1 |
| Konttinen, A | 1 |
| Kuisma, I | 1 |
| Ralli, R | 1 |
| Pohjola, S | 1 |
| Ojala, K | 1 |
5 reviews available for gemfibrozil and Diabetes Mellitus
| Article | Year |
|---|---|
Overview of Gilbert's syndrome.
Topics: Antineoplastic Agents; Comorbidity; Contraindications, Drug; Diabetes Mellitus; Drug Therapy, Combin | 2019 |
Current best treatment for non-alcoholic fatty liver disease.
Topics: Antioxidants; Chromans; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Fatty L | 2003 |
Combination lipid-lowering therapy in diabetes.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutary | 2003 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Hepta | 2005 |
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym | 2001 |
5 trials available for gemfibrozil and Diabetes Mellitus
| Article | Year |
|---|---|
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Topics: Alleles; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Gemfi | 2006 |
Peroxisome proliferator-activated receptors increase human sebum production.
Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlip | 2006 |
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
Topics: Aged; Codon; Diabetes Mellitus; Dyslipidemias; Fatty Acid-Binding Proteins; Gemfibrozil; Genetic Pre | 2007 |
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
Topics: Aged; Body Weight; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Gemfibroz | 1995 |
The effect of gemfibrozil on serum lipids in diabetic patients.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Cholesterol; Clinical Trials as Topic; Diabetes Me | 1979 |
8 other studies available for gemfibrozil and Diabetes Mellitus
| Article | Year |
|---|---|
Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states.
Topics: Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Gemfibrozil; Glucose; Humans; Hype | 2023 |
Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost of Illness; Di | 2020 |
The relationship between illnesses and medical drug consumption with the occurrence of traffic accidents among truck and bus drivers in Tehran, Iran.
Topics: Accidents, Traffic; Adult; Automobile Driving; Cross-Sectional Studies; Diabetes Mellitus; Drug Util | 2019 |
Fibrate use in diabetes: new concepts.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus; Fenofibrate; Fibric Acids; Gemfibrozil; Hum | 2011 |
A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates.
Topics: Adult; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Female; Fenofibrate; Gemfibrozil; H | 2012 |
High-density lipoprotein cholesterol: ready for prime time?
Topics: Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Ch | 2005 |
Troglitazone interferes with gemfibrozil's lipid-lowering action.
Topics: Chromans; Diabetes Mellitus; Drug Interactions; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reduc | 1998 |
A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
Topics: Diabetes Mellitus; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Fatal Outcome; | 2000 |